Posted by Michael Wonder on 14 Jan 2025
Adaptimmune announces US FDA breakthrough therapy designation granted to letetresgene autoleucel for treatment of myxoid/round cell liposarcoma
13 January 2025 - Adaptimmune Therapeutics today announced that letetresgene autoleucel has been granted breakthrough therapy designation by the US FDA for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma who have received prior anthracycline-based chemotherapy, are positive for HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06, and whose tumour expresses the NY-ESO-1 antigen.
Breakthrough therapy designation for letetresgene autoleucel in myxoid/round cell liposarcoma was based on the results in this indication from the Phase 2 IGNYTE-ESO trial.
